Co-financing means that countries contribute to the cost of GAVI-supported vaccines by procuring some of the required vaccine doses with non-GAVI funds
What is the purpose of GAVI's co-financing policy?
The co-financing policy encourages countries to plan for financially sustainable immunisation programmes in preparation for phasing out GAVI support for new vaccines. Recognising that the time frame for attaining financial sustainability varies across countries, the intermediate objective for the world's low-income countries is enhanced country ownership of vaccine financing.
When is the co-financing policy applied and how does it work?
Since 2007, all countries applying to GAVI for new vaccine support have been required to co-finance a portion of the cost of the requested vaccines.
The only exceptions from co-financing are vaccines for measles second dose, meningitis A, yellow fever preventive campaigns and measles-rubella catch-up campaign.
The co-financing requirements are established on the basis of a country's income and are calculated on a per dose level. The three country groupings and their related co-financing requirements established under the revised co-financing policy are listed below.
Country co-financing groups
GNI per capita threshold
Low Income Countries
GNI per capita below the World Bank low-income threshold
US$ 0.20 per dose
(no annual increase)
GNI per capita above the World Bank low-income threshold but below the GAVI eligibility threshold
(currently >$1,025 to <$1,550)
Starts at US$ 0.20 per dose and increases 15% annually
GNI per capita above the GAVI eligibility threshold
Starts at 20% of the projected price of the vaccine (in the year GAVI support ends) and increases linearly over four years to reach the projected price
When was the co-financing policy approved and when will it be updated?
GAVI has applied a co-financing policy since 2007. GAVI's revised co-financing policy was approved by the GAVI Board in December 2010 and the new co-financing obligations took effect in 2012. The policy is scheduled for review and, if required, updating in 2014.